Goldman Sachs analysts added Zealand Pharma to the firm’s European Conviction List as part of its monthly “Directors’ Cut” update. The firm says Zealand continues to be a key anti-obesity beneficiary.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF: